Pulmatrix, Inc.

As of August 6, 2025, Pulmatrix, Inc. is considered overvalued with a valuation grade of "does not qualify," highlighted by a Price to Book Value of 4.54, negative EV to EBIT and EV to EBITDA ratios, and a Return on Equity of -170.58%, despite a strong 1-year return of 131.13% compared to the S&P 500's 17.14%.

As of August 5, 2019, Pulmatrix, Inc. is considered overvalued with a "risky" rating due to high financial ratios and negative profitability metrics, despite a significant one-year stock return of 248.99%.

As of June 20, 2025, the trend is mildly bullish due to a bullish weekly MACD and daily moving averages, despite bearish signals from weekly Bollinger Bands and Dow Theory, with mixed indicators overall.

As of March 2022, the management team of Pulmatrix, Inc. includes Mr. Michael Higgins (Independent Chairman), Mr. Teofilo Raad (President and CEO), and several directors: Mr. Todd Bazemore, Dr. Christopher Cabell, Dr. Rick Batycky, Mr. Mark Iwicki, and Mr. Amit Munshi. They are responsible for the company's strategic direction and operations.

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies for serious respiratory diseases, with a market cap of $29.80 million and a recent net profit of -$2 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap entity.

As of Jun 18, Pulmatrix, Inc. has a market capitalization of 29.80 million and reported net sales of 1.92 million with a net profit of -12.20 million over the latest four quarters. Shareholder's funds are 8.95 million and total assets are 9.94 million as of Dec 24.